BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Issues Quarterly Earnings Results

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) released its earnings results on Thursday. The company reported ($0.49) EPS for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.18, Zacks reports.

BridgeBio Oncology Therapeutics Stock Performance

BBOT stock traded up $0.21 during trading on Friday, reaching $10.10. The stock had a trading volume of 175,321 shares, compared to its average volume of 324,031. The company has a market cap of $807.89 million, a price-to-earnings ratio of -9.81 and a beta of 0.28. BridgeBio Oncology Therapeutics has a 52 week low of $8.50 and a 52 week high of $14.87.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on BBOT. HC Wainwright raised their price objective on shares of BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the company a “buy” rating in a research note on Friday. Weiss Ratings started coverage on shares of BridgeBio Oncology Therapeutics in a report on Wednesday, January 14th. They issued a “sell (d+)” rating for the company. Stifel Nicolaus began coverage on BridgeBio Oncology Therapeutics in a research note on Tuesday, February 10th. They set a “buy” rating and a $23.00 target price on the stock. Finally, Raymond James Financial upgraded BridgeBio Oncology Therapeutics to a “moderate buy” rating in a research note on Friday, January 9th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $26.00.

Hedge Funds Weigh In On BridgeBio Oncology Therapeutics

Institutional investors have recently made changes to their positions in the business. Paradigm Biocapital Advisors LP boosted its stake in shares of BridgeBio Oncology Therapeutics by 21.2% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 2,261,749 shares of the company’s stock worth $28,317,000 after acquiring an additional 395,608 shares during the last quarter. Laurion Capital Management LP lifted its position in BridgeBio Oncology Therapeutics by 40.1% during the fourth quarter. Laurion Capital Management LP now owns 1,464,938 shares of the company’s stock valued at $18,341,000 after purchasing an additional 419,138 shares in the last quarter. State Street Corp increased its position in BridgeBio Oncology Therapeutics by 23.5% in the fourth quarter. State Street Corp now owns 218,278 shares of the company’s stock worth $2,733,000 after buying an additional 41,583 shares in the last quarter. Renaissance Technologies LLC bought a new position in shares of BridgeBio Oncology Therapeutics in the fourth quarter worth about $930,000. Finally, Goldman Sachs Group Inc. purchased a new position in shares of BridgeBio Oncology Therapeutics during the 4th quarter valued at about $1,185,000. Institutional investors own 54.89% of the company’s stock.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.